Drug Discovery for Diabetic Retinopathy

糖尿病视网膜病变的药物发现

• 批准号: 6826317
• 负责人: David Antonetti
• 金额: $ 28.95万
• 依托单位: PENNSYLVANIA STATE UNIV HERSHEY MED CTR
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-30 至 2006-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6826317
• 关键词: SDS polyacrylamide gel electrophoresis; blindness; cell line; chemical registry /resource; combinatorial chemistry; corticosteroid receptors; diabetic retinopathy; drug adverse effect; drug discovery /isolation; drug screening /evaluation; edema; eye disorder chemotherapy; high throughput technology; lead; macular drusen; medical complication; phosphorylation; polymerase chain reaction; protein biosynthesis; protein structure; therapy design /development; tight junctions; vascular endothelial growth factors; vascular endothelium permeability; western blottings

DESCRIPTION (provided by applicant): Diabetic retinopathy is one of the leading causes of blindness in the United States and vascular permeability resulting in macular edema is highly associated with vision loss. Breakdown of the normal blood-retinal barrier is believed to disrupt normal retinal neuronal function. Research from the laboratory of the co-PI has demonstrated that growth factors such as vascular endothelial growth factor, which are elevated in the eyes of patients with diabetes, breakdown the blood-retinal barrier by altering tight junction proteins. Conversely, glucocorticoids have the opposite effect and induce barrier properties by stimulating the synthesis and assembly of tight junction proteins. Glucocorticoids cannot be given systemically to patients with diabetes because of their glucose elevating effects and local treatment is invasive and may include side effects such as glaucoma and cataract formation. Therefore, a need exists to identify novel compounds that specifically induce vascular barrier properties without these side effects. In order to identify these compounds we will partner with Dr. Charles Smith, Director of the Drug Discovery Core Facility at the Penn State College of Medicine to screen a chemical library for compounds that induce endothelial barrier properties. Screening methods have been established and preliminary data have already identified candidate compounds that are effective in reducing dextran flux across endothelial monolayers. Specific aim 1 will use a series of screens to identify compounds that induce vascular barrier properties but that do not induce gluconeogenesis in hepatocytes. Specific aim 2 will investigate the mechanism of action of lead compounds. Experiments will reveal whether the glucocorticoid receptor is necessary in the action of the candidate compound and the effect of the compound on tight junction protein synthesis and assembly will be examined. These experiments will provide novel, lead compounds that will be further developed to treat macular edema in diabetic retinopathy.

描述（由申请人提供）： 糖尿病性视网膜病是美国失明的主要原因之一，导致黄斑水肿的血管渗透性与视力丧失高度相关。据信正常血液 - 视网膜屏障的崩溃会破坏正常的视网膜神经元功能。 COPI实验室的研究表明，诸如血管内皮生长因子之类的生长因子在糖尿病患者眼中升高，通过改变紧密的连接蛋白来分解血液 - 视网膜屏障。相反，糖皮质激素具有相反的作用，并通过刺激紧密连接蛋白的合成和组装来诱导屏障特性。糖皮质激素由于其葡萄糖升高作用，局部治疗具有侵入性，因此无法全身地给予糖尿病患者，并且可能包括青光眼和白内障形成等副作用。因此，存在一些需要鉴定出没有这些副作用的新型化合物，这些新型化合物专门诱导了血管屏障的特性。为了确定这些化合物，我们将与宾夕法尼亚州立医学院药物发现核心设施主任查尔斯·史密斯（Charles Smith）博士合作，以筛选一个化学库，以诱导内皮屏障特性。已经建立了筛选方法，并初步数据已经确定了可有效减少内皮单层葡萄糖通量的候选化合物。特定的目标1将使用一系列筛选来识别诱导血管屏障特性但不会诱导肝细胞糖异生的化合物。具体目标2将研究铅化合物的作用机理。实验将揭示在候选化合物的作用中是否需要糖皮质激素受体以及该化合物对紧密连接蛋白合成和组装的影响。这些实验将提供新颖的铅化合物，这些化合物将进一步开发以治疗糖尿病性视网膜病中的黄斑水肿。